Virtuel hjemmebaseret træningsintervention (stigning) for at forbedre kræftrelateret kognitiv svækkelse og tarmmikrobiome hos unge og unge voksne hjernesvulster overlevende
Næsten leveret hjemmebaseret træningsintervention på kognitiv svækkelse og tarmmikrobiome hos unge og unge voksne hjernetumoroverlevende: En pilot randomiseret kontrolleret forsøg
This clinical trial evaluates the impact of a research intervention of virtually supervised exercise program (RISE) on cancer-related cognitive impairment (CRCI), physical activity in adolescent and young adult (AYA) brain tumor survivors. This clinical trial also evaluates the impact of RISE on the collection of microorganisms that exist in the intestines (gut microbiome). Up to 45% of AYA brain tumor survivors experience CRCI, including issues with attention and memory. CRCI can have a negative impact on education, independent living and can worsen long-term quality of life. Moderate-intensity levels of exercise, particularly aerobic and resistance training, have been shown to improve cognitive function. Additionally, exercise can change the composition and function of the gut microbiome, which may lead to improved cognitive function. Unfortunately, only about 50% of AYAs with cancer receive exercise information or meet the physical activity recommendations. Tailoring a virtually delivered exercise intervention to meet the unique needs of AYAs may improve access to exercise. Participating in the virtual home-based exercise intervention, RISE, may improve physical activity and cognitive impairment in AYA brain tumor survivors and may also help researchers understand the relationship of exercise on the gut microbiome and cognitive function.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. Evaluate the feasibility of conducting a two-site pilot randomized controlled trial (RCT) to test the RISE in AYA brain tumor survivors.
II. Examine the impact of RISE on CRCI (primary) and physical activity (secondary).
EXPLORATORY OBJECTIVE:
I. Explore the impact of RISE on the gut microbiome diversity and composition.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I (RISE INTERVENTION): Patients receive access to Physitrack and participate in personalized, progressive aerobic training over 30-40 minutes 3-5 days a week and strength training exercises 2 days a week for 12 weeks. Patients also receive active lifestyle behavior coaching over 10 minutes on 2 days a week for weeks 1-4 and then once weekly for weeks 5-12.
ARM II (ATTENTION CONTROL): Patients receive calls from the trainer once weekly for 12 weeks. Patients also wear a Fitbit for 7 days at baseline to week 12.
After completion of study intervention, patients are followed up at week 18.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Jinbing Bai, PhD, RN
- Telefonnummer: 404-727-2466
- E-mail: jinbing.bai@emory.edu
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Hospital
-
Kontakt:
- Emily Bush, BS
- E-mail: emily.bush@emoryhealthcare.org
-
Ledende efterforsker:
- Jinbing Bai, PhD, RN
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
Kontakt:
- Keri Schadler, PhD
- Telefonnummer: 713-794-1035
- E-mail: klschadl@mdanderson.org
-
Kontakt:
- Maria Chang Swartz
- E-mail: mchang1@mdanderson.org
-
Ledende efterforsker:
- Keri Schadler, PhD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 15-39 years
- With primary brain tumor with cranial radiotherapy
- 6 months to 4 years post cranial radiotherapy
- Functional Assessment of Cancer Therapy (FACT)-Cognitive Function score < 60 based on self-report (used among AYAs with non-neural cancer)
- Able to provide informed consent/assent
- Able to walk and receive clearance from a provider to participate based on the Physical Activity Readiness Questionnaire
- Currently engaging in < 150 minutes of physical activity per week
- Willing to use smartphone-based applications (app)
Exclusion Criteria:
- Secondary malignancies, germline genetic syndrome, or recurrent disease requiring re-irradiation of the brain
- Moderate to severe traumatic brain injury with brain damage beyond that expected from brain tumor and treatment
- Developmental disorders (e.g., autism) or major psychotic illness (e.g., schizophrenia, depression) to avoid confounding impact related to these disorders
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm I (RISE)
Patients receive access to Physitrack and participate in personalized, progressive aerobic training over 30-40 minutes 3-5 days a week and strength training exercises 2 days a week for 12 weeks. Patients also receive active lifestyle behavior coaching over 10 minutes on 2 days a week for weeks 1-4 and then once weekly for weeks 5-12. |
Ancillary studies Participate in personalized, progressive aerobic training
Andre navne:
Receive active lifestyle behavior coaching
Andre navne:
Receive access to Physitrack Participating in strength training exercises
Andre navne:
|
|
Aktiv komparator: Arm II (attention control)
Patients receive calls from the trainer once weekly for 12 weeks. Patients also wear a Fitbit for 7 days at baseline to week 12. |
Ancillary studies Receive calls from the trainer
Andre navne:
Wear a Fitbit monitor |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Enrollment
Tidsramme: Up to 1.5 years
|
Feasibility will be ≥ 50% enrollment of eligible survivors. Descriptive statistics (e.g., frequency and percentage) will be used. |
Up to 1.5 years
|
|
Adherence to research intervention of virtually supervised exercise program (RISE)
Tidsramme: Up to 12 weeks
|
Feasibility will be ≥ 75% adherence to RISE. Descriptive statistics (e.g., frequency and percentage) will be used. |
Up to 12 weeks
|
|
Retention
Tidsramme: Up to 12 weeks
|
Feasibility will be ≥ 80% retention at end of intervention. Descriptive statistics (e.g., frequency and percentage) will be used. |
Up to 12 weeks
|
|
Acceptability
Tidsramme: Up to 18 weeks
|
Will use an 11-item acceptability questionnaire. A ≥ 4 ("agree" to "strongly agree") per item equates to acceptability. Descriptive statistics (e.g., frequency and percentage) will be used. |
Up to 18 weeks
|
|
Change in physical activity levels
Tidsramme: Baseline up to 18 weeks
|
Will be measured by Fitbit. Physical activity estimates considered as valid if the monitor is worn ≥ 10 hours/day on ≥ 4 days. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
Baseline up to 18 weeks
|
|
Change in cancer-related cognitive impairment
Tidsramme: Baseline up to 18 weeks
|
Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
Baseline up to 18 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Gut microbiome
Tidsramme: Up to 18 weeks
|
Fecal specimens will be collected for the gut microbiome. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
Up to 18 weeks
|
|
Physical function
Tidsramme: At baseline and at 12 and 18 weeks
|
Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
At baseline and at 12 and 18 weeks
|
|
Patient Quality of Life
Tidsramme: At baseline and at 12 and 18 weeks
|
Will be assessed by Patient Reported Outcomes Measurement Information System-29 recommended. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
At baseline and at 12 and 18 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Jinbing Bai, PhD, RN, Emory University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer i nervesystemet
- Neoplasmer i centralnervesystemet
- Neoplasmer i hjernen
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Motorisk aktivitet
- Bevægelse
- Muskuloskeletale fysiologiske fænomener
- Muskuloskeletale og neurale fysiologiske fænomener
- Undersøgelsesteknikker
- Epidemiologiske metoder
- Terapeutik
- Evalueringsmekanismer til sundhedsvæsenet
- Sundhedskvalitet
- Folkesundhed
- Miljø og folkesundhed
- Fysioterapimodaliteter
- Patientpleje
- Psykoterapi
- Adfærdsdiscipliner og aktiviteter
- Træningsterapi
- Rehabilitering
- Efterpleje
- Kontinuitet i patientpleje
- Fysisk konditionering, menneske
- Immunologiske teknikker
- Genetiske teknikker
- Epidemiologiske undersøgelser
- Epidemiologiske undersøgelsesegenskaber
- Kromatinimmunudfældning
- Nukleotid-sekventering med høj kapacitet
- Sekvensanalyse
- Sekvensanalyse, DNA
- Immunudfældning
- Kohortundersøgelser
- Øvelse
- Modstandstræning
- Adfærdsterapi
- Kromatinimmunudfældningssekvensering
- Opfølgningsundersøgelser
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- STUDY00008229
- P30CA138292 (U.S. NIH-bevilling/kontrakt)
- STUDY00008229 (Anden identifikator: Emory University Hospital/Winship Cancer Institute)
- NCI-2025-00181 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- WINSHIP6364-24 (Anden identifikator: Emory University Hospital/Winship Cancer Institute)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .